

Project H-Nano

Hybrid nanoparticles for the treatment of resistant prostate cancers: characterization of individual nanoparticles and biological evaluation


Céline JAUDOIN, Killian LAGUERRE and Ruxandra GREF

Institut des Sciences Moléculaires d'Orsay, Université Paris-Saclay

& Collaborators: Alexandre DAZZI, Ariane DENISET-BESSEAU, Jérémie MATHURIN, Giorgia URBINATI, Marta de FRUTOS, Maëva CHAUPARD

Multifunctional “cage” core-shell nanoparticles to fight cancer

efficiently load the anticancer drug



Target cancer cells

“Green” technologies

Advanced characterization methodology

Interdisciplinary consortium

**Institut des Sciences
Moléculaires d'Orsay**
UMR 8214 CNRS

Nanotechnology

- Dr. Ruxandra GREF
- Dr. Céline JAUDOIN
- Killian LAGUERRE

Institut Chimie Physique
UMR 8000 CNRS

Characterization: AFM-IR

- Dr. Alexandre DAZZI
- Dr. Ariane DENISET-BESSEAU
- Dr. Jérémie MATHURIN

Institut Gustave Roussy
UMR 9018 CNRS

Biological evaluation

- Dr. Giorgia URBINATI

**Laboratoire de physique
des Solides**
UMR 8502 CNRS

Characterization: STEM-EELS


- Dr. Marta de FRUTOS
- Maeva CHAUPARD

A new strategy to fight prostate cancer

Challenge of castration resistant prostate cancers

- Resistance to Androgen deprivation therapy (ADT or medical castration)
- Several mechanisms involved (ex: HER2-driven resistance)
- HER2 overexpressed in breast cancer but also in other cancers as prostate one
- HER2 overexpression → activate the androgen receptor in absence of androgens

A new strategy to fight prostate cancer




Trastuzumab (Tmab)




- Monoclonal antibody
- Target HER2
- Efficient on breast cancer

Nanocarrier



- High loading
- Loading efficiency
- Green technology




Gemcitabine monophosphate (Gem-MP)



- Anticancer drug
- Efficient in prostate cancer rodent model
- Does not cross cell membrane

Porous hybrid MOF nanoparticles (nanoMOFs)

A “green” synthesis of MOF (Metal organic framework)



P Horcajada, T Chalati, C Serre ... G Férey, P Couvreur, R Gref
Porous nanoMOFs as a potential platform for drug delivery and
imaging. *Nature Mater* **9**, 172–178 (2010)

Chalati et al., *J Mater Chem* **21**, 2220-7, 2011
Agostoni et al., *Green Materials*, 2013


Gem-MP loading & nanoMOF coating



Killian Laguerre,
M1

Drug loading

Tmab coating



- Efficiency ~100%
- Loading up to 30 wt%
- Stable under storage

- Tmab labelling with rhodamine
- Tmab functionalization ~ 230-450 Tmab/nanoparticle
- Morphology, size and cristallinity maintained after coating

Agostoni et al., Adv. Healthcare Mater. 2013;
Rodriguez et al., J Drug Target 2015; Li et al.
ChemMedChem 2019; Li et al., Front.
Bioeng. Biotechnol., 2020

In-depth characterization by AFM-IR and STEM/EELS


Characterization of individual NPs

- ✓ Map the location of NP components
- ✓ Drug location
- ✓ NP location inside a cell
- ✓ No label

- AFM-IR: 



A. Dazzi, A. Deniset-Besseau, J. Mathurin
Institut de Chimie Physique, U Paris-Saclay



E Pancani, J Mathurin, S Bilent, MF Bernet-Camard, A Dazzi, A Deniset-Besseau, R Gref. *Part. Part. Syst. Charact.* 3/2018

1st application to
investigate
nanoMOFs

- STEM-EELS:




M. Chaupard, M. de Frutos
Laboratoire de Physique des Solides, U Paris-Saclay


1st application
to investigate NPs

Biological evaluation

Impact of free Gem-MP, empty or Gem-MP loaded MOFs on DU-145 survival at 48h




- DU-145 cells: castration resistant prostate cancer cells
- Survival 48h after exposition
- Determination of highest non-toxic [MOFs] = $17 \mu\text{g.mL}^{-1}$
- $\text{IC}_{50}(\text{loaded Gem-MP}) \approx 0.1 \mu\text{M}$
- Difference between Gem-MP loaded and empty nanoMOFs



Conclusion & Perspectives

Formulation

- Loading 20 wt% Gem-MP
- *Coating optimization*




In depth characterization

- AFM-IR
- STEM-EELS



In vitro evaluation

- Effect on DU-145 cell viability
- *Tmab coating evaluation*
- *NPs internalization: difference between Tmab-coated and not-coated NPs*



In vivo evaluation

- *Effect on tumor growth*
- *NPs biodistribution*

Acknowledgements

Institut des Sciences Moléculaires d'Orsay



Pr. Ruxandra Gref

Killian Laguerre

Dr. Céline Jaudoin

Dr. Xue Li

Dr. Mario Menendez

Dr. Jingwen Qiu

Dr. Giuseppina Salzano

Dr. Agostoni



Institut de Chimie Physique

Dr. Jérémie Mathurin

Dr. Ariane Deniset-Besseau

Pr. Alexandre Dazzi



Laboratoire de Physique des Solides

Maëva Chaupard

Dr. Marta de Frutos



METSY

Dr. Giorgia Urbinati